AtaiBeckley (STU:B72) ROCE %: -47.11% (As of Mar. 2026)


STU:B72 AtaiBeckley Inc STU:B72
51 GF Score
Price €3.45
GF Value €6.32
! 4 Warning Signs
View Full Analysis

What is AtaiBeckley ROCE %?

AtaiBeckley STU:B72 51 ROCE % is -47.11% as of Mar. 2026. GuruFocus rates STU:B72 with a GF Score™ of 51/100 and a GF Value™ of €6.32. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AtaiBeckley's annualized ROCE % for the quarter that ended in Mar. 2026 was -47.11%.

AtaiBeckley  (STU:B72) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AtaiBeckley ROCE % Related Terms

AtaiBeckley ROCE % Historical Data

* Premium members only.

The historical data trend for AtaiBeckley's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtaiBeckley ROCE % Chart

AtaiBeckley Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -49.58 -41.05 -12.91 -73.20 -313.97

AtaiBeckley Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.41 -64.04 -125.12 -886.06 -47.11
STU:B72
51GF Score
AtaiBeckley Inc STU:B72
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtaiBeckley ROCE % Calculation

AtaiBeckley's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-562.519/( ( (152.215 - 23.828) + (249.985 - 20.051) )/ 2 )
=-562.519/( (128.387+229.934)/ 2 )
=-562.519/179.1605
=-313.97 %

AtaiBeckley's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-103.044/( ( (249.985 - 20.051) + (229.119 - 21.594) )/ 2 )
=-103.044/( ( 229.934 + 207.525 )/ 2 )
=-103.044/218.7295
=-47.11 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.11% mean?
AtaiBeckley (STU:B72) has a ROCE % of -47.11% as of Mar. 2026.
Is AtaiBeckley's ROCE % too high?
AtaiBeckley's current ROCE % is -47.11%. Overall, AtaiBeckley has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does AtaiBeckley's ROCE % compare to GLUE and NUVB?
AtaiBeckley's ROCE % of -47.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. AtaiBeckley's current ROCE % is -47.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtaiBeckley stock overvalued right now?
AtaiBeckley (STU:B72) has a current ROCE % of -47.11%. The stock's GF Value™ is €6.32, compared to a current price of €3.45 — trading 45.5% below its estimated fair value. The current ROCE % is -47.11%. AtaiBeckley's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For AtaiBeckley (STU:B72), the current ROCE % is -47.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtaiBeckley (STU:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €3.45 is trading 45.5% below its estimated GF Value™ of €6.32.

Key valuation signals for STU:B72:

  • ROCE %: -47.11%
  • GF Value™: €6.32 vs. price of €3.45 (45.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtaiBeckley Business Description

Other Exchanges ATAI:USAB72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
51GF Score

Get the complete analysis for STU:B72

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.45
Price
€6.32
GF Value